Clear Street’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Clear Street’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.06K	Sell	78,733 -100	-0.1%	-$3	﹤0.01%	1028
2025 Q4	$2.46K	Sell	78,833 -200	-0.3%	-$6	﹤0.01%	844
2025 Q3	$1.85K	Buy	79,033 +200	+0.3%	+$7	﹤0.01%	759
2025 Q2	$2.63K	Buy	+78,833	New	+$2.2K	﹤0.01%	580
2024 Q4	–	Sell	-200	Closed	-$7	–	623
2024 Q3	$7	Buy	+200	New	+$7	﹤0.01%	700
2024 Q2	–	Sell	-100	Closed	-$4	–	824
2024 Q1	$4	Buy	+100	New	+$3	﹤0.01%	796
2023 Q3	–	Sell	-100	Closed	-$10	–	1258
2023 Q2	$10	Buy	+100	New	+$10	﹤0.01%	1287

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street's SABSW Position: Q1 2026 in Review

Clear Street reduced its SAB Biotherapeutics Warrant (SABSW) stake by 0.13% in Q1 2026, selling an estimated $3 and leaving 78,733 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1028.

Clear Street first reported a position in SABSW in Q2 2023 and has held it in 7 quarters since. The position peaked at $2.63K in Q2 2025. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

Clear Street held 78,733 shares of SAB Biotherapeutics Warrant worth $2.06K as of Q1 2026.
Clear Street sold 100 SAB Biotherapeutics Warrant shares in Q1 2026, an estimated $3.
SAB Biotherapeutics Warrant made up ﹤0.01% of Clear Street's portfolio in Q1 2026, its #1028 holding.
Clear Street first reported a position in SAB Biotherapeutics Warrant in Q2 2023 and has held it in 7 quarters since.
Clear Street's SAB Biotherapeutics Warrant position peaked at $2.63K in Q2 2025.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.